Literature DB >> 25907832

The PTEN-AKT-mTOR/RICTOR Pathway in Nasal Natural Killer Cell Lymphoma Is Activated by miR-494-3p via PTEN But Inhibited by miR-142-3p via RICTOR.

Hao-Hui Chen1, Wei-Ting Huang1, Li-Wei Yang1, Chung-Wu Lin2.   

Abstract

Nasal natural killer (NK) cell lymphoma (NNL) is an Epstein-Barr virus-associated lymphoma of cytotoxic NK cell origin. The Epstein-Barr virus-encoded miR-BART20-5p inhibits T-bet (TBX21), the master transcription factor of cytotoxic NK cells. To further explore the roles of miRNAs in NNLs, we measured the miRNA expression profiles of 36 NNLs. miR-21, miR-142-3p, miR-126, miR-451, and miR-494-3p were the top five miRNAs with the highest expression levels. By using pathway analysis, we identified associations between all of the five miRNAs with the PTEN-AKT-mTOR pathway, in which PTEN suppresses the oncogenic AKT, and mTOR mediates the oncogenic effects of AKT. YT and NK92 cells derived from NK cell lymphomas were used. miR-494-3p inhibited PTEN with secondary activation of AKT in NK92 cells, and miR-142-3p inhibited RICTOR, a key component of the mTOR complex, with secondary suppression of AKT in YT cells. Significantly, T-bet inhibited the PTEN-AKT-mTOR/RICTOR pathway through induction of PTEN and suppression of RICTOR. Therefore, a molecular circuit of T-bet, PTEN, AKT, and RICTOR is regulated by miR-BART20-5p, miR-494-3p, and miR-142-3p. This circuit is involved in the pathogenesis of NNL. Hence, antagomirs to miR-BART20-5p or miR-494-3p, miR-142-3p mimics, or AKT inhibitors may be useful in NNL therapy.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25907832     DOI: 10.1016/j.ajpath.2015.01.025

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

Review 1.  A review on EBV encoded and EBV-induced host microRNAs expression profile in different lymphoma types.

Authors:  Saber Soltani; Armin Zakeri; Alireza Tabibzadeh; Amir Mohammad Zakeri; Milad Zandi; Saba Siavoshi; Saba Seifpour; Abbas Farahani
Journal:  Mol Biol Rep       Date:  2021-02-01       Impact factor: 2.316

2.  Inhibition of histone deacetylase 3 by MiR-494 alleviates neuronal loss and improves neurological recovery in experimental stroke.

Authors:  Haiping Zhao; Guangwen Li; Sijia Zhang; Fangfang Li; Rongliang Wang; Zhen Tao; Qingfeng Ma; Ziping Han; Feng Yan; Junfen Fan; Lingzhi Li; Xunming Ji; Yumin Luo
Journal:  J Cereb Blood Flow Metab       Date:  2019-09-11       Impact factor: 6.200

Review 3.  Transcriptional and post-transcriptional regulation of NK cell development and function.

Authors:  Jeffrey W Leong; Julia A Wagner; Aaron R Ireland; Todd A Fehniger
Journal:  Clin Immunol       Date:  2016-03-03       Impact factor: 3.969

4.  MicroRNA-142-3p inhibits IFN-γ production via targeting of RICTOR in Aspergillus fumigatus activated CD4+ T cells.

Authors:  Ning Ma; Ting Wei; Bin Wang; Xiaohua Jiang; Lin Zhou; Renqian Zhong
Journal:  Ann Transl Med       Date:  2019-11

Review 5.  Regulation and metabolic functions of mTORC1 and mTORC2.

Authors:  Angelia Szwed; Eugene Kim; Estela Jacinto
Journal:  Physiol Rev       Date:  2021-02-18       Impact factor: 46.500

6.  miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6.

Authors:  Sebastiano Rontauroli; Ruggiero Norfo; Valentina Pennucci; Roberta Zini; Samantha Ruberti; Elisa Bianchi; Simona Salati; Zelia Prudente; Chiara Rossi; Vittorio Rosti; Paola Guglielmelli; Giovanni Barosi; Alessandro Vannucchi; Enrico Tagliafico; Rossella Manfredini
Journal:  Oncotarget       Date:  2017-03-28

Review 7.  MiRNAs and lncRNAs in NK cell biology and NK/T-cell lymphoma.

Authors:  FengXia Gao; SiRong He; AiShun Jin
Journal:  Genes Dis       Date:  2020-08-31

8.  Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications.

Authors:  Joanna Trelinska; Wojciech Fendler; Iwona Dachowska; Katarzyna Kotulska; Sergiusz Jozwiak; Karolina Antosik; Piotr Gnys; Maciej Borowiec; Wojciech Mlynarski
Journal:  Orphanet J Rare Dis       Date:  2016-09-29       Impact factor: 4.123

9.  MIR494 reduces renal cancer cell survival coinciding with increased lipid droplets and mitochondrial changes.

Authors:  Punashi Dutta; Edward Haller; Arielle Sharp; Meera Nanjundan
Journal:  BMC Cancer       Date:  2016-01-21       Impact factor: 4.430

10.  Hinokitiol up-regulates miR-494-3p to suppress BMI1 expression and inhibits self-renewal of breast cancer stem/progenitor cells.

Authors:  Shih-Ming Chen; Bing-Yen Wang; Che-Hsin Lee; Hsueh-Te Lee; Jung-Jung Li; Guan-Ci Hong; Yu-Chieh Hung; Peng-Ju Chien; Che-Ying Chang; Li-Sung Hsu; Wen-Wei Chang
Journal:  Oncotarget       Date:  2017-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.